Pall ups its continuous biomanufacturing game in Kaneka Protein A deal

By Dan Stanton contact

- Last updated on GMT

Image: iStock/AlexLMX
Image: iStock/AlexLMX

Related tags: Biotechnology

Pall Corporation has teamed up with Protein A chromatography sorbent supplier Kaneka to support its end-to-end continuous biomanufacturing offering.

The supply agreement will see Pall – recently acquired by Danaher​ – add Kaneka Corporation’s KanCapA affinity capture resin to its downstream bioprocessing tools, offering the sorbent in a range of pre-packed columns and high throughput screening tools to its biomanufacturing customers.

The KanCapA affinity capture resin uses Kaneka’s proprietary recombinant alkaline stable Protein A ligand in combination with a cellulose base matrix to form a monoclonal Antibody (mAb) purification resin the Japanese firm says has a high binding capacity for the increasingly high titres being achieved in the industry.

For continuous bioprocessing, upstream perfusion systems can culture cells continuously for up to 90 days, but the biggest challenge is keeping the process going into the downstream train.

But the addition of Kaneka’s Protein A will help solve this, expanding Pall’s portfolio of continuous bioprocessing and chromatography products, and provide “the key chromatographic step required in a typical MAb purification process”​ according to General Manager Michael Egholm.

“Our customers will be able to go directly from CHO cell culture in the bioreactor through continuous clarification using Acoustic Wave Separation (AWS) and STAX depth filtration products to provide a continuous feed stream for direct integration with the BioSMB platform.”

The BioSMB  tech is a multicolumn continuous chromatography platform acquired from Tarpon Biosystems last March​, while the AWS system – described as “a filterless filter”​  ­- was licensed from FloDesignSonics in June​.

Related news

Show more

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Related suppliers

Follow us


View more